Premium
Feasibility, efficacy, and safety of cell‐free and concentrated ascites reinfusion therapy (KM‐CART) for malignant ascites
Author(s) -
Matsusaki Keisuke,
Orihashi Kazumasa
Publication year - 2020
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/aor.13691
Subject(s) - ascites , medicine , cart , exacerbation , cancer , gastroenterology , surgery , mechanical engineering , engineering
Efficacy for alleviating signs/symptoms of malignant ascites of a renovated CART (cell‐free and concentrated ascites reinfusion therapy) system, called KM‐CART, was evaluated. A total of 4781 KM‐CART procedures were performed in 2109 patients. All patients were accepted unless hemodynamically unstable or consciousness impaired. The ascites were processed and drip‐infused into the patient. There were no major complications or deaths. The mean drainage volume was 6.2 L (maximum: 27.7 L), patient symptoms (numerical scale system) were significantly alleviated (45.1 ± 19.0 reduced to 21.2 ± 14.2, P < .001), and patient leg circumference significantly decreased (33.3 ± 4.4 cm reduced to 30.5 ± 4.4 cm, P < .001) without exacerbation of renal function. Collected cancer cells could be utilized for immune therapy. KM‐CART is capable of improving the “quality of best supportive care” and can be beneficial in conjunction with medication for alleviating malignant pain.